Trial: A Study to Evaluate Sacituzumab Tirumot…

Trial Details

Sponsor: Merck Sharp & Dohme LLC (industry)

Phase: 3

Start date: May 3, 2024

Planned enrollment: 450

Trial ID: NCT06356311

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Sacituzumab tirumotecan (SKB264, MK-2870, sac-TMT)

Overview

Sacituzumab tirumotecan (sac-TMT), also known as SKB264 or MK-2870, is an investigational antibody-drug conjugate (ADC) targeting TROP2, a cell surface glycoprotein overexpressed in various cancers. (prnewswire.com)

Mechanism of Action

Sac-TMT comprises a monoclonal antibody directed against TROP2 linked to a topoisomerase I inhibitor payload. This design facilitates targeted delivery of the cytotoxic agent to TROP2-expressing tumor cells, aiming to enhance antitumor efficacy while minimizing systemic toxicity. (prnewswire.com)

Efficacy

Endometrial and Ovarian Cancers

In the phase 2 KL264-01 trial (NCT04152499), sac-TMT monotherapy was evaluated in patients with previously treated advanced endometrial and ovarian cancers. Preliminary results presented at the 2024 ESMO Congress showed:

Endometrial Cancer Cohort (n = 44):
Objective Response Rate (ORR): 34.1% (confirmed ORR: 27.3%)
Disease Control Rate (DCR): 75.0%
Median Progression-Free Survival (PFS): 5.7 months (95% CI, 3.7–9.4)
Median Duration of Response (DOR): 5.7 months (range, 3.8 to 7.4+)
Ovarian Cancer Cohort (n = 40):
ORR: 40.0% (confirmed ORR: 35.0%)
DCR: 75.0%
Median PFS: 6.0 months (95% CI, 3.9–7.3)
Median DOR: 5.3 months (range, 2.1 to 24.4+)

(onclive.com)

Triple-Negative Breast Cancer (TNBC)

The phase 3 OptiTROP-Breast01 study (NCT05347134) compared sac-TMT to physician's choice of chemotherapy in patients with previously treated locally recurrent or metastatic TNBC. Results indicated:

Sac-TMT Arm (n = 130):
Median PFS: 5.7 months (95% CI, 4.3 to 7.2)
ORR: 43.8%
Median Overall Survival (OS): Not reached (95% CI, 11.2 to NE)
Chemotherapy Arm (n = 133):
Median PFS: 2.3 months (95% CI, 1.6 to 2.7)
ORR: 12.8%
Median OS: 9.4 months (95% CI, 8.5 to 11.7)

Sac-TMT demonstrated a statistically significant improvement in PFS and OS compared to chemotherapy. (ascopubs.org)

Safety

In the KL264-01 trial, treatment-related adverse events (TRAEs) occurred in all patients:

Endometrial Cancer Cohort:
Grade ≥3 TRAEs: 72.7%
Common TRAEs: Anemia (88.6%), decreased white blood cell count (81.8%), decreased neutrophil count (65.9%)
Ovarian Cancer Cohort:
Grade ≥3 TRAEs: 67.5%
Common TRAEs: Anemia (85.0%), decreased white blood cell count (60.0%), decreased neutrophil count (57.5%)

No TRAEs led to death, and there were no reports of drug-related interstitial lung disease or pneumonitis. (onclive.com)

In the OptiTROP-Breast01 study, common grade ≥3 TRAEs in the sac-TMT arm included:

Neutrophil count decreased: 32.3%
Anemia: 27.7%
White blood cell count decreased: 25.4%

(ascopubs.org)

HealthScout AI Analysis

Goal: To determine whether sacituzumab tirumotecan (MK-2870), a TROP2-directed antibody-drug conjugate, improves overall survival compared with treatment of physician’s choice in patients with previously treated (third line or later) advanced/metastatic gastroesophageal adenocarcinoma.

Patients: Adults with histologically or cytologically confirmed unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, ECOG 0–1, measurable disease by RECIST 1.1, and progression after at least two prior systemic regimens (chemotherapy and/or immunotherapy). HER2 status is unrestricted; HER2-positive patients must have received trastuzumab where appropriate. Key exclusions include significant ocular surface disease that impairs corneal healing, grade ≥2 peripheral neuropathy, active inflammatory bowel disease, uncontrolled cardiovascular/cerebrovascular disease, symptomatic effusions requiring recent drainage, prior TROP2-targeted ADC or topoisomerase I inhibitor–based ADC/chemotherapy, active CNS metastases, active infections, and history/current ILD requiring steroids.

Design: Multicenter, open-label, randomized phase 3 superiority study comparing sacituzumab tirumotecan versus physician’s choice therapy. Stratification includes centrally assessed TROP2 status, among others. Planned enrollment ~450 participants.

Treatments: Experimental: Sacituzumab tirumotecan 4 mg/kg IV on days 1, 15, and 29 of each 42-day cycle, with supportive care and permitted rescue medications. Sacituzumab tirumotecan is a TROP2-targeted antibody-drug conjugate linking an anti-TROP2 antibody to a belotecan-derived topoisomerase I inhibitor via a cleavable linker (average DAR ~7.4). The linker enables extracellular and intracellular release of a membrane-permeable payload, supporting a bystander effect. In phase 3 TNBC, it improved PFS and OS over chemotherapy and showed high objective response rates; early-phase lung cancer data suggest notable activity, with myelosuppression (neutropenia, anemia) as common grade ≥3 toxicities. Comparator: Treatment of physician’s choice with one of trifluridine–tipiracil (oral), irinotecan, paclitaxel, or docetaxel per standard dosing schedules, with supportive care.

Outcomes: Primary: Overall survival. Secondary: PFS by BICR per RECIST 1.1, objective response rate by BICR, duration of response, incidence of adverse events, and treatment discontinuations due to adverse events. Time frames extend up to approximately 25–48 months depending on endpoint.

Burden on patient: Moderate. Participants will require baseline and on-treatment imaging for RECIST assessments, routine labs, and safety monitoring comparable to later-line standard care. The investigational arm involves IV infusions on days 1, 15, and 29 of a 42-day cycle, leading to roughly two to three clinic visits per month; comparator regimens also require regular IV or oral administration with monitoring. A pretreatment tumor sample is required for central TROP2 testing, which may involve retrieving archival tissue or a new biopsy if archival material is inadequate. No intensive pharmacokinetic schedules are specified, and visit frequency aligns with standard oncology practice, but cumulative visit and infusion time, plus potential management of myelosuppression, contribute to a moderate overall burden.

Eligibility

Show Criteria

Inclusion Criteria:

* Has a histologically-or cytologically-confirmed diagnosis of advanced, unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

* Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by the local site investigator/radiology. Lesions situated in a previously-irradiated area are considered measurable if progression has been shown in such lesions.

* Has received, and progressed on, at least 2 prior chemotherapy and/or immunotherapy regimens for advanced, unresectable or metastatic gastroesophageal adenocarcinoma.

* Participants are eligible regardless of human epidermal growth factor receptor-2 (HER2) status. Participants who are HER2+ must have previously received trastuzumab where available/appropriate

* Has adequate organ function

* Has provided tumor tissue sample for determination of trophoblast cell-surface antigen 2 (TROP2) status by the central laboratory before randomization for stratification

* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (except for alopecia and vitiligo). Participants with endocrine related AEs who are adequately treated with hormone replacement therapy are eligible

* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology

* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days before randomization

* Has ability to swallow oral medication for those who may receive trifluridine-tipiracil

* Human immunodeficiency virus (HIV) infected participants must have well-controlled HIV on antiretroviral therapy (ART)

* Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load

* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion Criteria:

* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing

* Has Grade ≥2 peripheral neuropathy

* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)

* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval (QTcF) to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within 6 months before the first dose of study intervention

* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before the first dose of study intervention

* Has received prior treatment with a trophoblast antigen 2(TROP2) targeted antibody-drug conjugate (ADC), a topoisomerase 1 inhibitor based, and/or a topoisomerase 1 inhibitor-based chemotherapy.

* Has received prior systemic anticancer therapy within 2 weeks before the first dose of study intervention

* Has received prior radiotherapy within 2 weeks before the first dose of study intervention, has radiation-related toxicities, requiring corticosteroids, and/or has had radiation pneumonitis

* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

* Is currently receiving a strong and/or moderate inducer/inhibitor of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of treatment with study intervention. The required washout period before starting study intervention is 2 weeks

* Has received an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention

* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

* Has an active infection requiring systemic therapy

* HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castlemans's Disease

* Has concurrent active hepatitis B (defined as hepatitis B surface antigen (HBsAg) positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection

* Has had major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention. Anticipation of the need for major surgery during the course of treatment with study intervention is also exclusionary

* Has severe hypersensitivity (Grades \>=3) to the study interventions, any of their excipients, and/or to another biologic therapy

* Has a history of (noninfectious) pneumonitis/ interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD

Sites (166)

Sort by distance to:

Institut Jules Bordet-GastroIntestinal Medical Oncology ( Site 1003)

Anderlecht, Bruxelles-Capitale, Region de, 1070, Belgium

No email / 1-888-577-8839

Status: Recruiting

Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)

Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

No email / 1-888-577-8839

Status: Recruiting

UZ Leuven-Digestive Oncology ( Site 1000)

Leuven, Vlaams-Brabant, 3000, Belgium

No email / 1-888-577-8839

Status: Recruiting

AZ Delta vzw ( Site 1002)

Roeselare, West-Vlaanderen, 8800, Belgium

No email / 1-888-577-8839

Status: Recruiting

Centro de Pesquisa Clínica do Instituto do Câncer do Ceará ( Site 0405)

Fortaleza, Ceará, 60430235, Brazil

No email / 558532884576

Status: Recruiting

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0406)

Natal, Rio Grande do Norte, 59075-740, Brazil

No email / 1-888-577-8839

Status: Recruiting

Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0400)

Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

No email / 555133572092

Status: Recruiting

Hospital de Caridade de Ijuí ( Site 0412)

Ijuí, Rio Grande do Sul, 98700 000, Brazil

No email / +5555981580022

Status: Recruiting

Centro de Hematologia e Oncologia ( Site 0404)

Joinville, Santa Catarina, 89202-050, Brazil

No email / 1-888-577-8839

Status: Recruiting

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0411)

São José do Rio Preto, São Paulo, 15090000, Brazil

No email / 1-888-577-8839

Status: Recruiting

Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0401)

Barretos, São Paulo, 14784-400, Brazil

No email / 1-888-577-8839

Status: Recruiting

A. C. Camargo Cancer Center ( Site 0409)

São Paulo, 01509-010, Brazil

No email / +551121895000

Status: Recruiting

IBCC - Núcleo de Pesquisa e Ensino ( Site 0402)

São Paulo, 04014-012, Brazil

No email / 1-888-577-8839

Status: Recruiting

McGill University Health Centre ( Site 0201)

Montreal, Quebec, H4A 3J1, Canada

No email / 514-934-1934 x45721

Status: Recruiting

James Lind Centro de Investigacion del Cancer ( Site 0506)

Temuco, Región de la Araucanía, 4800827, Chile

No email / 1-888-577-8839

Status: Recruiting

FALP-UIDO ( Site 0500)

Santiago, Region M. de Santiago, 7500921, Chile

No email / 1-888-577-8839

Status: Recruiting

Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 0502)

Santiago, Region M. de Santiago, 7620002, Chile

No email / 1-888-577-8839

Status: Recruiting

Bradfordhill-Clinical Area ( Site 0501)

Santiago, Region M. de Santiago, 8420383, Chile

No email / 1-888-577-8839

Status: Recruiting

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503)

Santiago, Region M. de Santiago, 7500653, Chile

No email / +56991612199

Status: Recruiting

Anhui Provincial Cancer Hospital-medical oncology ( Site 3016)

Hefei, Anhui, 230000, China

No email / +8618110410760

Status: Recruiting

Second Affiliated hospital of Anhui Medical University-Oncology ( Site 3038)

Hefei, Anhui, 230000, China

No email / 0551-63839536

Status: Recruiting

Chongqing University Three Gorges Hospital ( Site 3036)

Chongqing, Chongqing Municipality, 404000, China

No email / 023-58103019

Status: Recruiting

Fujian Cancer Hospital ( Site 3007)

Fuzhou, Fujian, 350014, China

No email / +86059183660063

Status: Recruiting

Zhongshan Hospital Affiliated to Xiamen University ( Site 3013)

Xiamen, Fujian, 361004, China

No email / +86 0592-2211200

Status: Recruiting

The First Affiliated hospital of Xiamen University-oncology ( Site 3011)

Xiamen, Fujian, 361003, China

No email / +860592213727

Status: Recruiting

The 900th Hospital of the Joint Logistics Support Force of PLA ( Site 3008)

Fuzhou, Fujian, 350025, China

No email / +86 0591-22859606

Status: Recruiting

Sun Yatsen University Cancer Center ( Site 3001)

Guangzhou, Guangdong, 510555, China

No email / 02087342479

Status: Recruiting

Cancer Hospital of Shantou University Medical College ( Site 3034)

Shantou, Guangdong, 515041, China

No email / +86 0754-88573563

Status: Recruiting

Southern Medical University Nanfang Hospital-Department of Oncology ( Site 3019)

Guangzhou, Guangdong, 510515, China

No email / +862061641888

Status: Recruiting

Affiliated Cancer Hospital of Guangxi Medical University ( Site 3047)

Nanning, Guangxi, 530201, China

No email / +86 0771-5331955

Status: Recruiting

Fourth Hospital of Hebei Medical University ( Site 3015)

Shijiazhuang, Hebei, 050035, China

No email / 1-888-577-8839

Status: Recruiting

Harbin Medical University Cancer Hospital-Harbin Medical University Cancer Hospital ( Site 3005)

Harbin, Heilongjiang, 150081, China

No email / 0451 86298278

Status: Recruiting

Henan Cancer Hospital-henan cancer hospital ( Site 3002)

Zhengzhou, Henan, 450000, China

No email / +864000371818

Status: Recruiting

Hubei Cancer Hospital ( Site 3012)

Wuhan, Hubei, 430079, China

No email / +8613995607152

Status: Recruiting

Xiangyang Central Hospital ( Site 3045)

Xiangyang, Hubei, 441106, China

No email / 0710-2815626

Status: Recruiting

Hunan Cancer Hospital ( Site 3014)

Changsha, Hunan, 410013, China

No email / +86 13319602869

Status: Recruiting

The First Affiliated Hospital of Soochow University ( Site 3040)

Suzhou, Jiangsu, 215006, China

No email / 0512-67972858

Status: Recruiting

The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 3037)

Nanchang, Jiangxi, 330006, China

No email / 1-888-577-8839

Status: Recruiting

Jilin Province Tumor Hospital ( Site 3018)

Changchun, Jilin, 130000, China

No email / 1-888-577-8839

Status: Recruiting

LinYi Cancer Hospital-Gastrology department ( Site 3024)

Linyi, Shandong, 276000, China

No email / 1-888-577-8839

Status: Recruiting

Zhongshan Hospital,Fudan University-Oncology ( Site 3003)

Shanghai, Shanghai Municipality, 200032, China

No email / 021-31151990

Status: Recruiting

Fudan University Shanghai Cancer Center-medical oncology ( Site 3009)

Shanghai, Shanghai Municipality, 200032, China

No email / 021-54561523

Status: Recruiting

Renji Hosp,Shanghai Jiao Tong University School of Medicine ( Site 3042)

Shanghai, Shanghai Municipality, 200127, China

No email / 021-68383312

Status: Recruiting

Nanchong Central Hospital (Jiangdong Campus) ( Site 3029)

Nanchong, Sichuan, 637199, China

No email / 0817-3634555

Status: Recruiting

Sichuan Cancer hospital. ( Site 3030)

Chengdu, Sichuan, 610213, China

No email / 028-85420501

Status: Recruiting

West China Hospital, Sichuan University ( Site 3035)

Chengdu, Sichuan, 610041, China

No email / (028)85422114

Status: Recruiting

Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010)

Ürümqi, Xinjiang, 830011, China

No email / 0991-7819430

Status: Recruiting

Yunnan Province Cancer Hospital ( Site 3031)

Kunming, Yunnan, 650107, China

No email / 0871-68178134

Status: Recruiting

Zhejiang Cancer Hospital-Oncology ( Site 3021)

Hangzhou, Zhejiang, 310022, China

No email / 1-888-577-8839

Status: Recruiting

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Oncology ( Site 3006)

Hangzhou, Zhejiang, 310016, China

No email / 0571886921

Status: Recruiting

Yueqing People's Hospital ( Site 3041)

Yueqing, Zhejiang, 325699, China

No email / 057762061260

Status: Recruiting

Taizhou Hospital of Zhejiang Province ( Site 3020)

Linhai, Zhejiang, 317000, China

No email / 0576-85120120

Status: Recruiting

Centro Cancerológico del Caribe (CECAC) ( Site 0606)

Barranquilla, Atlántico, 080001, Colombia

No email / 3132121774

Status: Recruiting

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0602)

Bogotá, Bogota D.C., 110131, Colombia

No email / +576017454421

Status: Recruiting

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0603)

Bogotá, Bogota D.C., 111321, Colombia

No email / 576015948660x5715593

Status: Recruiting

Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0600)

Valledupar, Cesar Department, 200001, Colombia

No email / +57 315 8505190

Status: Recruiting

Fundación Valle del Lili-Fundacion Valle del Lili ( Site 0607)

Santiago de Cali, Valle del Cauca Department, 760032, Colombia

No email / +576023319090 - 4022

Status: Recruiting

Rigshospitalet ( Site 1102)

Copenhagen, Capital Region, 2100, Denmark

No email / +45 35453545

Status: Recruiting

Aalborg Universitetshospital, Syd-Department of Oncology ( Site 1103)

Aalborg, North Denmark, 9000, Denmark

No email / +45 97660000

Status: Recruiting

Odense Universitetshospital-Department of oncology ( Site 1101)

Odense, Region Syddanmark, 5000, Denmark

No email / +45 24432924

Status: Recruiting

Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1211)

Bordeaux, Aquitaine, 33076, France

No email / +33 5 56 33 32 78

Status: Recruiting

Centre François Baclesse ( Site 1202)

Caen, Calvados, 14076, France

No email / +33 2 31 45 50 50

Status: Recruiting

CHU Rangueil-Digestive oncology department ( Site 1210)

Toulouse, Haute-Garonne, 31059, France

No email / +33561322142

Status: Recruiting

Centre Oscar Lambret ( Site 1206)

Lille, Hauts-de-France, 59020, France

No email / +33 03 20 29 58 30

Status: Recruiting

Institut Mutualiste Montsouris-Oncology ( Site 1216)

Paris, Île-de-France Region, 75014, France

No email / +33 01 56 61 63 77

Status: Recruiting

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1203)

Rennes, Ille-et-Vilaine, 35042, France

No email / +33299252976

Status: Recruiting

CENTRE LEON BERARD-Medical oncology ( Site 1208)

Lyon, Rhone-Alpes, 69008, France

No email / 33 4 78 78 59 92

Status: Recruiting

Centre Hospitalier Universitaire de Poitiers ( Site 1209)

Poitiers, Vienne, 86021, France

No email / +33549444951

Status: Recruiting

Hôpital Saint-Louis ( Site 1201)

Paris, 75475, France

No email / +33142494041

Status: Recruiting

NCT-Department of Medical Oncology ( Site 1302)

Heidelberg, Baden-Wurttemberg, 69120, Germany

No email / +496221566857

Status: Recruiting

Universitätsmedizin Göttingen - Georg-August-Universität ( Site 1310)

Göttingen, Lower Saxony, 37075, Germany

No email / +4905513963879

Status: Recruiting

Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 1307)

Dresden, Saxony, 01307, Germany

No email / +49035145818004

Status: Recruiting

Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306)

Kiel, Schleswig-Holstein, 24116, Germany

No email / +4943116971272

Status: Recruiting

Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 1304)

Berlin, 13353, Germany

No email / +4930450653192

Status: Recruiting

Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 1300)

Hamburg, 20249, Germany

No email / +4940360352247

Status: Recruiting

Queen Mary Hospital ( Site 3100)

Hong Kong, Hong Kong

No email / +852 2255 3838

Status: Recruiting

Queen Elizabeth Hospital ( Site 3101)

Yau Ma Tei, 999077, Hong Kong

No email / +852 3506 8888

Status: Recruiting

Prince of Wales Hospital ( Site 3102)

Shatin, Hong Kong

No email / + 852 3505 2211

Status: Recruiting

Hadassah Medical Center ( Site 1603)

Jerusalem, 9112001, Israel

No email / +972-538220805

Status: Recruiting

Rambam Health Care Campus-Oncology Division ( Site 1600)

Haifa, 3109601, Israel

No email / 04-7776234

Status: Recruiting

Hillel Yaffe Medical Center ( Site 1604)

Hadera, 3810101, Israel

No email / +972-544512396

Status: Recruiting

Sourasky Medical Center ( Site 1602)

Tel Aviv, 64239, Israel

No email / 03-6947832

Status: Recruiting

Rabin Medical Center ( Site 1605)

Petah Tikva, 4941492, Israel

No email / +972-505533121

Status: Recruiting

Azienda Ospedaliera Universitaria dell'Università "Luigi Van-UOC Oncoematologia ( Site 1704)

Napoli, Campania, 80131, Italy

No email / 00390815666729

Status: Recruiting

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1703)

Rome, Lazio, 00168, Italy

No email / 00390630154953

Status: Recruiting

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1700)

Milan, Lombardy, 20133, Italy

No email / +390223903822

Status: Recruiting

Azienda Ospedaliero Universitaria Pisana ( Site 1702)

Pisa, Tuscany, 56126, Italy

No email / 0039050992455

Status: Recruiting

Ospedale San Raffaele-Oncologia Medica ( Site 1701)

Milan, 20132, Italy

No email / 02 2643 3169

Status: Recruiting